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Down syndrome (DS), one of the most common birth defects and the most widespread
genetic cause of intellectual disabilities, is caused by extra genetic material on
chromosome 21 (HSA21). The increased genomic dosage of trisomy 21 is thought to
be responsible for the distinct DS phenotypes, including an increased risk of developing
some types of childhood leukemia and germ cell tumors. Patients with DS, however, have
a strikingly lower incidence of many other solid tumors. We hypothesized that the third
copy of genes located in HSA21 may have an important role on the protective effect
that DS patients show against most types of solid tumors. Focusing on Copy Number
Variation (CNV) array data, we have generated frequencies of deleted regions in HSA21 in
four different tumor types from which DS patients have been reported to be protected.
We describe three different regions of deletion pointing to a set of candidate genes
that could explain the inverse comorbidity phenomenon between DS and solid tumors.
In particular we found RCAN1 gene in Wilms tumors and a miRNA cluster containing
miR-99A, miR-125B2 and miR-LET7C in lung, breast, and melanoma tumors as the main
candidates for explaining the inverse comorbidity observed between solid tumors and DS.
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INTRODUCTION
Down syndrome (DS) was first described and named by the
British physician John Langdon Down about 150 years ago.
However, Professor Jerome Lejeune discovered a century later that
the cause of this disorder was the presence of an extra chromo-
some 21 (HSA21) (Mégarbané et al., 2009). Today, DS is the most
widespread cause of genetic intellectual disability, with an approx-
imated prevalence of between 1 in 1000 and 1 in 1100 live births
worldwide, and roughly 3000–5000 new cases per year (www.
who.int). The Down phenotype is caused by a complete or par-
tial trisomy (TS21) of human chromosome 21 (HSA21) acquired
essentially by meiotic non-disjunction events during gametoge-
nesis. Besides the cognitive impairment typical of DS patients,
a variable set of associated conditions, such as congenital heart
disease, vision problems, hearing loss, or decreased immune sys-
tem activity, has been linked to the disease (Roizen and Patterson,
2003). In the past two decades, substantial advances in explor-
ing the human genome, together with the exponential growth
of bioinformatics, have permitted a better understanding of the
functional links between the extra copy of HSA21 and the varia-
tions in the different phenotypes of DS individuals (Letourneau
and Antonarakis, 2012; Letourneau et al., 2014). The sequenc-
ing of HSA21 and the experimental research done with models
of DS have allowed the scientific community to connect specific
genomic regions and sets of genes to different clinical conditions
and syndrome phenotypes. Initially, a total of 225 genes were
identified (Hattori et al., 2000), and 2 years later the gene con-
tent was updated to 329 genes (Kapranov et al., 2002). Nowadays,
based on data provided by large-scale studies, the HSA21 gene
number is estimated to be around 534 from a total of 2176 gene
transcripts (Scarpato et al., 2014).
New epidemiological insights attempting to define direct and
inverse comorbidities between complex disorders have started to
reveal the complicated connections that DS and cancer may share.
This epidemiological evidence points to both a higher- and a
lower-than-expected probability of developing some tumors in
patients with DS (Ibáñez et al., 2010; Tabarés-Seisdedos et al.,
2011; Tabarés-Seisdedos and Rubenstein, 2013). Catalá-López
et al. (2014) conducted a meta-analysis based on published epi-
demiological studies reporting comorbidities between cancer and
CNS disorders, gathering data for 17,090 DS patients. This study
showed an increased risk for developing leukemia and testicu-
lar cancer in DS patients. Other studies in different ethnographic
populations have evidenced a lower incidence of most tumors in
patients with DS (Hasle et al., 2000; Boker et al., 2001; Nižetic´
and Groet, 2012). In particular, breast cancer incidence shows a
considerable decrease in DS patients compared with age-matched
euploid individuals.
Interestingly, the observed protection against many solid
tumors in DS patients has opened a window of opportunity in
the search for tumor suppressor genes located on chromosome 21
that would amplify their effect in a dosage-dependent way. Over
the last few years, and in parallel to the above, a great amount
of research has focused on the associations between genomic
alterations, like somatic copy number variations (CNVs), and
cancer (Rubio-Moscardo et al., 2005; Climent et al., 2007; Jönsson
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et al., 2012; Hieronymus et al., 2014). The result of such anal-
yses is a noteworthy amount of open access microarray data
available at public repositories such as NCBI Gene Expression
Omnibus (GEO, at http://www.ncbi.nlm.nih.gov/geo/), or EBI
(ArrayExpress http://www.ebi.ac.uk/arrayexpress/).
In the present perspective, we first approached DS as a genetic
disorder caused by the extra copy of genomic DNA on chromo-
some 21. Our aim was to collect previously published CNV array
data from cancers for which there exists an observed decreased
incidence in DS as compared to that for non-DS patients. We then
screened for the most common structural alterations present in
chromosome 21. This might lead to identifying regions contain-
ing genes potentially responsible for the protection against solid
tumor development in DS individuals. Our underlying hypothe-
sis was that copy gains of tumor suppressor genes in chromosome
21 of DS patients would be responsible for the protection phe-
nomenon observed between DS and most types of solid tumors.
Therefore, we expected to find those genes in the maximum fre-
quency deletion regions of tumor samples coming from non-DS
patients. To our knowledge, our work presents the first attempt at
defining tumor suppressor candidate genes using this approach.
We selected four tumor types described as low incidence tumors
in DS by epidemiological studies: breast cancer (359 samples),
lung cancer (78 samples), melanoma (34 samples) and Wilms
tumor (18 samples). Breast and lung cancer showed a standard-
ized incidence ratio (SIR) of 0.4 and 0.24, respectively, between
DS and age-matched euploid population cohorts (Hasle et al.,
2000; Patja et al., 2006). The SIR value for the skin cancer
group, in which melanoma was included, was 0.25. Kidney can-
cer, including Wilms tumor, showed a SIR value of 0.84 (Hasle
et al., 2000; Patja et al., 2006), and no cases of DS were found in
a study that included 5854 Wilms tumor patients (Olson et al.,
1995).
MATERIALS AND METHODS
ARRAY CGH ANALYSIS
We analyzed data from multiple platforms to generate both the
disease-specific frequencies of amplification and deletion, as well
as the frequency summaries for four tumor types described as
low incidence tumors in DS by epidemiological studies based
on previously published data (Table 1). Raw Array CGH data
files were downloaded from Gene Expression Omnibus, and
normalization and conversion to log2 values of intensity were
performed. Probe annotations from assemblies older than hg19
were remapped to hg19 using Lift Genome Annotation tool, soft-
ware (http://genome.ucsc.edu/cgi-bin/hgLiftOver) which con-
verts coordinates and genome annotation files between assem-
blies. To define amplification and deletion regions, we used
the R-package CGHcall, which applies the Circular Binary
Segmentation (CBS) algorithm (Hsu et al., 2011) it seeks out
gain and loss segments by recursively dividing the genome until
it identifies segments that have probe distributions different from
their neighbors. This was followed by a CGHcall algorithm pro-
ducing an objective and effective classification of the segmented
data into copy number states. Once we had computed platform-
specific data for amplification and deletion, we transformed
them into multiplatform-comparable data. To do so, we defined
5000 anchor positions along chromosome 21, and performed an
estimation of the amplification and deletion value for each of
these anchors in every sample for every platform using custom
R code (see Supplementary data). Once we had the amplification
and deletion values for the anchors, we calculated the frequencies
of amplification and deletion for the set of all diseases.
EXPRESSION ARRAY ANALYSIS
We downloaded raw data from GEO, selecting the datasets
describing gene expression from both tumor samples, as well
as from normal tissue, in order to perform differential expres-
sion analysis (see Table 1 below). Data and raw signal intensi-
ties were checked for quality, and a quantile normalization was
done. A multiple t-test was performed to search for differentially
expressed genes located on chromosome 21, and the p-values were
corrected for FDR.
miRNA EXPRESSION ARRAY ANALYSIS
For the miRNA differential expression analysis, we retrieved
raw data from studies that included tumor samples and healthy
control tissues. We applied quantile normalization and carried
Table 1 | Datasets used for the copy number (CN), gene expression (Exp) and microRNA expression (miR) downloaded from Gene Expression
Omnibus (GEO).
Tumor type GEO Platform Data References
Breast GSE22133 SWEGENE_BAC_33K_Full CN Jönsson et al., 2012
Melanoma GSE45354 Agilent-021924 SurePrint G3 Human CGH Microarray 8× 60 K CN
Lung GSE29065 SWEGENE_BAC_32K_Full CN Staaf et al., 2013
Wilms GSE28397 Custom Agilent 2× 105 K Human Genomic microarray CN
Breast GSE22820 Agilent-014850 Whole Human Genome Microarray 4x44K G4112F Exp Liu et al., 2011
Melanoma GSE46517 Affy metrix U133A microarray chip Exp Kabbarah et al., 2010
Lung GSE19804 Affy metrix Human Genome U133 Plus 2.0 Array Exp Lu et al., 2010
Wilms GSE4530 Homo sapiens 4.8K 02-01 amplified cDN A Exp
Breast GSE48088 [miRNA-2_0] Affy metrix Multispecies miRNA-2_0 Array miR Peña-Chilet et al., 2014
Melanoma GSE35579 CRUK/Melton lab-Human melanoma-71 -v2 -microRN A expression miR Xu et al., 2012
Lung GSE51855 Agilent-015508 Human miRNA Microarray miR Arima et al., 2014
Wilms GSE38419 Febit Homo Sapiens miRBase 13.0 miR Schmitt et al., 2012
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out a differential expression analysis using the SAM method
implemented in the R package samr.
RESULTS AND DISCUSSION
Direct comorbidities between DS and cancer have been the sub-
ject of several studies that have shed light onto the primary
molecular causes of these associations (Catalá-López et al., 2014;
Letourneau et al., 2014). Nevertheless, inverse comorbidities are
mainly sketched thanks to epidemiological research, and lack
molecular explanations (Tabarés-Seisdedos et al., 2011). To bet-
ter understand how DS patients could be protected from some
types of solid tumors, we have analyzed the copy number profiles
of chromosome 21 from four cancer types observed with a lower-
than-expected incidence in DS patients by epidemiological data
(Nižetic´ and Groet, 2012; Catalá-López et al., 2014). We gener-
ated a mean amplification and deletion profile for the four cancer
types and observed three principal maximum deletion regions in
chromosome 21. We selected as candidate genes those present in
themaximum frequency of deletion regions (MDR) that were fur-
ther found downregulated in at least 2 of the expression datasets
analyzed (Figure 1).
Maximum frequency deletion region 1 (MDR1) is observed
at cytoband 21p11.2 and spans from position 10,704,090–
11,166,137. Strikingly, this region is the maximum deletion
region for 3 of the 4 cancer types included in the analysis. Lung
and breast cancers and melanoma show deletion frequencies of
26.9, 11.7, and 61.7%, respectively. Wilms tumor does not present
deletion in this region. MDR1 contains the genes TPTE and a
cluster of different isoforms of the BAGE gene. The BAGE gene
has been reported to be a tumor rejection antigen recognized
by cytotoxic T cells (Nagel et al., 2003). An impaired expres-
sion of the BAGE gene, due to CNVs, could lead to a reduction
in immune system targeting and recognition of cancerous cells
capacity. The TPTE gene has been described as a transmembrane
tyrosine phosphatase related to the PTEN gene and may play a
role in signal transduction pathways. PTEN is a validated tumor
suppressor gene with phosphatase activity that inhibits the PI3K
pathway (Davidson et al., 2010). The actual TPTE in vivo function
is still unclear, but a hypothetical role in PI3K pathway inhibition
could explain how an overexpression of this gene in cells carrying
an extra-copy of chromosome 21 could protect from cancer cell
proliferation and why MDR1 is the most common deleted region
in the three cancer types previously described.
Data regarding the CNVs for BAGE and TPTE agree with the
results of the differential expression analysis carried out for breast
and lung cancer, where both genes are downregulated. The reduc-
tion of the genetic product of those genes could confer advantages
in the tumor proliferation process. Moreover, MDR1 contains a
micro RNA, miR_548, which recently has been reported to play a
possible role in tumor suppression through the control of gene
FHIT action in human cancer (Hu et al., 2014). We were not
able to detect a downregulation of miR_548 in any of the miRNA
expression datasets.
Maximum frequency deletion region 2 (MDR2) is a wide
deletion region, mainly found in melanoma, spanning from posi-
tion 14,592,985 to position 26,365,557 and covering cytobands
21q11.2, 21q21.1 and a segment of 21q21.2. It shows a deletion
frequency of 50%, and also appears deleted in breast and lung
cancer, displaying a deletion frequency of 5 and 11%, respectively
(Figure 1B). MDR2 includes 26 coding genes and 3 miRNAs.
Given the high number of genes contained in this region, we
focused only on those 2 genes that were also downregulated in
at least two of the associated expression datasets.
The BTG3 gene is downregulated both in melanoma and
breast cancer, while CXADR is downregulated in lung cancer and
melanoma. BTG3 has previously been reported to be downregu-
lated in a wide variety of breast cancer cell lines (Yu et al., 2008)
and belongs to a protein family characterized by its antiprolifera-
tive properties. Moreover, the low expression of BTG3 has previ-
ously been related to the progression of several kinds of cancer,
such as adenocarcinoma, oral squamous cell cancer, non-small
cell lung cancer, prostate cancer, and hepatocellular carcinoma
(Chen et al., 2013; Lv et al., 2013). Additionally, the downreg-
ulation of BTG3 is a feature of breast cancer patient samples in
the study from Liu et al. (2011). Furthermore, data from the
expression analysis suggest that BTG3 downregulation may play
an important role in melanoma progression, and to our knowl-
edge, this is a result not previously described in the literature.
The molecular function reported for BTG3, along with the large
number of solid tumors where its downregulation is observed,
indicates that BTG3 may be a good candidate for explaining
inverse comorbidity events between DS and cancer.
MDR2 also contains a microRNA cluster containing miR-
LET7C,miR-152B2, and miR-99A (Figure 1C). It has been shown
that the downregulation of miR-LET7C in prostate cancer is
followed by an increase in the androgen receptor (AR) expres-
sion levels leading to an increased proliferation of the tumor
cells. Additionally, the overexpression of miR-LET7C leads to an
impairment of AR molecules entailing a reduction in the prolif-
erative capacity of the cancerous cells (Nadiminty et al., 2012).
Moreover, low levels of miR-LET7C have been reported in lung
tumors associated with high levels of Ras protein, which activate
cell proliferation via the MAPK pathway (Johnson et al., 2005).
miR-125B2 has been reported to be downregulated in several
tumor types, such as breast, prostate, ovarian and neuroblastoma,
among others (Iorio et al., 2005; Ozen et al., 2008), indicating a
putative tumor suppressor function. Finally, the downregulation
of miR-99A has been linked to increased proliferative capacities
in different cancer types (Sun et al., 2011; Chen et al., 2012; Xin
et al., 2013). We found miR-99A downregulated in the lung can-
cer, breast cancer and melanoma datasets, miR-125B2 in breast
cancer and melanoma datasets and miR-LET7C in the melanoma
and Wilms tumor datasets. Altogether, this could indicate that
the extra copy of chromosome 21 in DS patients could lead to
an increased expression of the microRNA cluster, leading to a
synergic effect over cell proliferation. These miRNAs could be
good candidates for explaining the inverse comorbidity observed
between solid tumors and DS.
To delve deeper into this notion, we used the known gene tar-
gets of the 3 miRNAs to perform a REACTOME (Croft et al.,
2014) pathway enrichment analysis. The results of the analy-
sis showed that the set of validated target genes for the three
miRNAs is enriched in pathways related to cell proliferation or
apoptosis inhibition, like PI3K/AKT activation (REACT_12464),
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FIGURE 1 | Copy number analysis of Chromosome 21. (A) Representation
of genomic gain (blue) and deletion (red) frequencies on four different tumor
types and median average of all tumors together. (B) Deletion frequency for
the three major deleted regions (MDR) in breast cancer (BC), melanoma
(ML), lung tumors (LT), and Wilms Tumor (WT) on HSA21. (C) Representation
of the three MDR based on genomic localization and size with those genes
and miRNAs that showed downregulation in the gene expression correlation
analysis.
signaling by ERBB2 (REACT_115755) and signaling by NOTCH,
Interferon alpha/beta and IFG1R (REACT_299, REACT_25162
and REACT_150210, respectively). These enrichments are con-
sistent with their theoretical role as candidate genes for the
inverse comorbidity phenomenon observed between DS and solid
tumors.
The last maximum frequency deletion region we describe
in our study, MDR3, is a very small region on Wilm’s tumors
and is deleted in 50% of the samples analyzed. It covers a
narrow segment between positions 35,943,407 and 35,981,911,
and it includes only one gene, RCAN1 (Figure 1C). The protein
encoded by this gene, previously known as DSCR1 (DS critical
region gene 1), interacts with calcineurin-inhibiting calcineurin-
dependent signaling pathways (Carme Mulero et al., 2010).
RCAN1 is located in the minimal candidate region of the DS phe-
notype, an area of approximately 3Mb at chromosomal region
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21q22 (OMIM 602917), and it is overexpressed in the DS patient’s
brain. Its overexpression is linked to the formation of neurofibril-
lary tangles in Alzheimer’s disease patients and with the facilita-
tion of neural apoptosis in the DS phenotype (Sun et al., 2014).
Comparative sequence analyses of HSA21 and the mouse genome
models of DS resulted in the discovery of DSRC1 (RCAN1) as
a potential candidate for being a tumor suppressor gene in both
lung tumor, as well as melanoma cells, through the suppression
of tumor angiogenesis (Minami et al., 2014; Shin et al., 2014).
These findings, combined with the observed frequency of deletion
shown inWilms tumor, to our knowledge has not been previously
reported. Moreover, the general downregulation trend present in
three of the four tumor types analyzed here, lung cancer, breast
cancer and Wilms tumor, point to RCAN1 as the best supported
link between the Down phenotype and protection from cancer.
In conclusion, although we admit the possible existence of
bias as a result of the small number of samples, our genomic
approach demonstrates that the analysis of Chromosome 21-
deleted regions from specific tumors may allow the predic-
tion of candidate genes to explain why individuals with DS
have a reduced risk for developing these tumors. Further func-
tional studies, however, are needed to prove the potential tumor
suppressor properties of these candidate genes and miRNA.
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